New Pradaxa indication to hit Germany, UK and Denmark first
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim will first launch its oral anticoagulate Pradaxa (dabigatran etexilate) for the prevention of stroke in patients with atrial fibrillation (AF) at risk of stroke in Germany, the UK and Denmark, the company told Scrip. The European Commission approved the drug's new indication on 4 August 2011.